December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad
- Author
- Health Advance
- Published
- Thu 29 Dec 2022
- Episode Link
- https://www.gynecologiconcology-online.net/pb-assets/Health%20Advance/journals/ygyno/podcasts/1222_GynOnc_EditorsChoice_Omalley_Matulonis-1671729592777.mp3
Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial
Featuring: David O'Malley, MD, The Ohio State University 
Editor’s Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data
